首页|Value of 18F‑FDG PET/CT in predicting EGFR mutation status and PD‑L1 expression in non‑small cell lung cancer
Value of 18F‑FDG PET/CT in predicting EGFR mutation status and PD‑L1 expression in non‑small cell lung cancer
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
Objective: To explore the relationship between multimodal imaging features and metabolic parameters derived from 18F‑FDG PET/CT and the mutation status of epidermal growth factor receptor (EGFR) and the expression of programmed cell death ligand 1 (PD‑L1) in non‑small cell lung cancer (NSCLC), so as to provide objective evidence for clinical screening of targeted therapy and immunotherapy beneficiaries. Methods: Data of NSCLC patients who underwent 18F‑FDG PET/CT scans, EGFR mutation and PD‑L1 expression tests with confirmed pathological results were collected. The differences of PET/CT morphological characteristics and metabolic parameters between the EGFR mutation and the wild group, and between the PD‑L1 expression positive and the negative group were analyzed. Univariate and multivariate logistic regression analyses were used to test the correlation between clinical and PET/CT parameters and EGFR mutation and PD‑L1 expression status. Results: MTV(P=0.01) and TLG(P=0.00) values of EGFR mutant patients were statistically lower than those of wild type patients. Univariate and multivariate logistic analysis showed that age(P=0.03), smoking history(P=0.00) and MTV(P=0.00) were independent risk factors for EGFR mutation. The positive expression of PD‑L1 in stage Ⅲ/Ⅳ group was significantly higher than that in stage Ⅰ/Ⅱ Group (P=0.01), but there was no significant difference in different age, gender, smoking history, SUVmax, MTV, TLG, LDH and CEA groups. Logistic univariate analysis showed that only stage was associated with the positive expression rate of PD‑L1 (P=0.01). There was no significant correlation between PET/CT parameters and PD‑L1 status. Conclusion: PET/CT metabolic parameters MTV, age and smoking history are independent predictors of EGFR mutation, which is expected to provide objective evidence for clinical screening of targeted treatment beneficiaries; however, PET/CT metabolic parameters are not good in predicting PD‑L1 protein expression, which needs to be further verified by large sample.
PET/CTNon-small cell lung cancerEGFRPD-1/PD-L1
LI Xue?yan、WANG Da?wei、YU Li?juan、LIN Xiu?yan、GONG Wei、PAN Deng、CHEN Lu
展开 >
Medical Imaging Department,Hainan Cancer Hospital Medical Imaging Department,Haikou 570311,China
Research and Cultivation Foundation of Hainan Medical College海南省自然科学基金青年基金Doctoral Research Fund Project of Hainan Cancer Hospital
万方数据
